The development of epigenetic protein-associated inhibitors is of growing interest for new therapies for diseases such as cancer. Inhibitors have been developed for a number of domain families involved in histone binding and modification. However, there are still many domain families, especially the reader domains, for which few effective inhibitors have been discovered. As many proteins in epigenetic regulation have tandem reader domains, targeting cavities formed at domain-domain interfaces provides an alternative to develop inhibitors rather than just targeting individual reader domains.

With the expertise and years of experience in structure-based drug discovery, Creative BioMart currently offers the small molecule inhibitors screening service of multiple domains to accelerate the development of epigenetic drugs.

Figure 1. Proteins that Bind or Modify Histone Tails Containing Multiple PTMs. (Bowkett D.; et al. 2018).

Advantages of Choosing Creative BioMart

1. One-stop service: at Creative BioMart, customers can access a full range of epigenetic drug discovery services, from project consulting to protocol design to project implementation and data analysis. We can further explore solutions appropriate for your research focus according to your specific research objectives.
2. Skillful technical team: with strong expertise in medicinal chemistry, biochemistry, molecular and cell biology, our team is able to perform structural and computational drug design against targets. Our aim is to identify promising hits through screening and further to optimize the preclinical drug candidates.
3. State-of-the-art technology platforms: as part of Creative BioMart, a leading provider of protein-related biotechnology services, we have established advanced structure-determination platforms, including X-ray crystallography, nuclear magnetic resonance (NMR) and cryo-electron microscopy (cryo-EM) platforms for the screening of small molecule compounds.

Figure 2. Workflow of Our Service at Creative BioMart

Creative BioMart pursues a strong commitment to service and unparalleled data quality to help our customers achieve research goals in the rapidly evolving world of epigenetics. Please contact us for more information and a detailed quote.

Reference
1. Bowkett D.; et al. Identifying small-molecule binding sites for epigenetic proteins at domain-domain interfaces. ChemMedChem. 2018, 13: 1051-1057.